Please login to the form below
Genmab
This page shows the latest Genmab news and features for those working in and with pharma, biotech and healthcare.
Genmab enters oncology collaboration with Bolt Biotherapeutics
Danish biotech company Genmab has announced that it has entered an oncology research and development collaboration with Bolt Biotherapeutics. ... to transform cancer treatment,” said Jan van de Winkel, chief executive officer of Genmab.
Latest news
-
Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
The CD20 monoclonal antibody (mAb) was originally developed by Danish biotech company Genmab, and subsequently developed and marketed worldwide by Novartis under a licence agreement. ... According to Genmab, Kesimpta is the first B-cell therapy that can
-
Novartis gains EU approval for relapsing MS drug Kesimpta
The CD20 monoclonal antibody (mAb) was originally developed by Danish biotech company Genmab, and subsequently developed and marketed worldwide by Novartis under a licence agreement. ... According to Genmab, Kesimpta is the first B-cell therapy that can
-
Janssen scores another expansion for new Darzalex combination in the US
Darzalex, which was originally developed by Danish biotech Genmab, is a monoclonal antibody (mAb) that targets the CD38 protein, which is highly expressed on multiple myeloma cells.
-
J&J’s bispecific lung cancer antibody nabs FDA breakthrough status
Janssen developed JNJ-6372 in collaboration with Genmab, which is also its collaborator on blockbuster multiple myeloma therapy Darzalex (daratumumab) and follow-up HexaBody-CD38.
-
BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma
lagging behind rivals in the market such as Johnson &Johnson and Genmab’s CD38 inhibitor Darzalex (daratumumab). ... Earlier this month, Sanofi claimed FDA approval for Sarclisa (isatuximab) in relapsed/refractory myeloma, while J&J and Genmab already
Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
Novartis gains EU approval for relapsing MS drug Kesimpta
Janssen scores another expansion for new Darzalex combination in the US
J&J’s bispecific lung cancer antibody nabs FDA breakthrough status
BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma
More from news
Approximately 9 fully matching, plus 47 partially matching documents found.
Latest Intelligence
-
European biotech: a new generation of leaders emerges
Another of its partners, Horizon Therapeutics recently submitted to the FDA the Genmab-developed teprotumumab for the treatment of active thyroid eye disease. ... If approved, this would become Genmab’s third product on the market, behind Darzalex and
-
Deal Watch August 2016
469. Genmab (DK). Gilead (US). Licence. DuoBody technology platform to develop bispecific antibody candidates for targeting HIV plus option to second licence.
-
Pharma deals in August 2015
Exclusive global licence. 510. Genmab. Novo Nordisk. Bispecific antibody candidates outside oncology indications.
-
Deal Watch table for September 2014
244. Seattle Genetics / Genmab. Licence and collaboration. Additional deal to use Seattle's antibody drug conjugate technology.
-
Pharma deals during September 2014
Four years ago Genmab started working with Seattle Genetics' ADC technology and has now signed a new deal using a Genmab antibody. The creative aspect of this deal is that Seattle ... has retained an option to increase the Genmab royalties to double
European biotech: a new generation of leaders emerges
Deal Watch August 2016
Deal Watch table for September 2014
Pharma deals during September 2014
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
CureVac taps Klaus Edvardsen for chief development officer role
He has also held leadership roles at GlaxoSmithKline (GSK) and at Genmab, working across medicines development within various therapeutic areas.
-
Genmab appoints Tahamtan Ahmadi as chief medical officer, head of experimental medicines
Ahmadi joined Genmab in 2017, previously serving as senior vice president, head of oncology. ... Prior to Genmab, Ahmadi worked as head of experimental medicine and early development oncology at Janssen.
-
Genmab hires first chief operating officer
In his new role, Mancini will oversee all of Genmab’s commercial, corporate development, business development and information technology functions. ... operations during this transformational stage for Genmab,”said Jan van de Winkel, chief executive
-
EUSA Pharma appoints Rolf Hoffmann to its board
Hoffman, who is currently chairman of Biotest and sits on the board of directors of Genmab, brings over 30 years’ pharmaceutical experience to his new position having served in a number
-
Dr Jan van de Winkel joins Austrian biotech Hookipa
Current president and chief executive officer of Genmab, Dr van de Winkel joins the board with over 25 years’ experience in the therapeutic antibody field. ... Dr van de Winkel’s career experience has seen him serve Medarex Europe as its vice
CureVac taps Klaus Edvardsen for chief development officer role
Genmab appoints Tahamtan Ahmadi as chief medical officer, head of experimental medicines
Genmab hires first chief operating officer
EUSA Pharma appoints Rolf Hoffmann to its board
Dr Jan van de Winkel joins Austrian biotech Hookipa
More from appointments
Approximately 1 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Events Executive
-
Depending on Experience
-
Digital account director
-
Competitive
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Understanding the ‘real world’ starts and ends with the patient
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Sanofi raises profit forecast following positive Q2 results
- Biogen/Eisai push for second approval in Alzheimer’s disease
- Reducing primary care antibiotic use may not be enough to counter antimicrobial resistance
- SoftBank buys $5bn stake in Roche
- Live Webinar: Making Wearable Technology Scalable and Adoptable
- Live Webinar: Transforming the Future of Health & Aging from a Global Health & Social Impact Approach
- Investors respond positively to “strong” Eli Lilly results
- Amanda Pritchard becomes NHS England’s first female chief executive
- Biogen/Eisai push for second approval in Alzheimer’s disease
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Understanding the ‘real world’ starts and ends with the patient
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- Ask the writers: Transitioning from academia to medical writing
- Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
- Strategic launch planning: familiar framework, new mindset
- By James Aird...
- Guide
- How to embrace behavioural science principles in healthcare MR...
